

[Ceftriaxone](#)

Essential medicine status

Section:

[6. Anti-infective medicines](#) [6.2. Antibacterials](#) [6.2.2. Watch group antibiotics](#)

ATC codes: [J01DD04](#)

EMLc

Indication

Other specified pneumonia ICD11 code: [CA40.Y](#)

INN

Ceftriaxone

Medicine type

Chemical agent

Antibiotic groups

[WATCH](#)

List type

Core

Additional notes

Do not administer with calcium and avoid in infants with hyperbilirubinaemia.

Formulations

Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt) ; 500 mg in vial powder for injection (as sodium salt) ; 1 g in vial powder for injection (as sodium salt) ; 2 g in vial powder for injection (as sodium salt) (EML)

EML status history

First added in 2017 ([TRS 1006](#))

Changed in 2021 ([TRS 1035](#))

Changed in 2023 ([TRS 1049](#))

Sex

All

Age

Also recommended for children

Age restriction

> 41 weeks corrected gestational age

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Ceftriaxone](#)

DrugBank

[Ceftriaxone](#)

Expert Committee recommendation

The Expert Committee recommended the inclusion of a new strength, child-friendly dispersible tablet formulation of amoxicillin + clavulanic acid (200 mg + 28.5 mg) as an Access group antibiotic on the core list of the EMLc for treatment of bacterial infections in children – specifically those infections for which amoxicillin + clavulanic acid is already recommended on the EMLc. The Committee noted that the 7:1 ratio of amoxicillin to clavulanic acid is associated with similar efficacy to the 4:1 ratio but has a reduced frequency of gastrointestinal adverse effects. The Committee endorsed the importance of age-appropriate formulations to better meet the dosing needs of children.

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of a new formulation of amoxicillin + clavulanic acid (dispersible tablet 250 mg + 62.5 mg) to the EMLc. - the addition of new strength formulations of cefotaxime (powder for injection: 500 mg; 1 g; 2 g (as sodium) in vial) to the EML and EMLc. - the addition of a new strength formulation of ceftriaxone (powder for injection: 500 mg (as sodium) in vial) to the EML and EMLc.

EML recommendations: Other specified pneumonia

First choice

Second choice

Hospital-acquired pneumonia

First choice

[piperacillin + tazobactam](#)

[amoxicillin + clavulanic acid](#)

[cefotaxime](#)

[ceftriaxone](#)

Second choice